The entity owns Beta (Systematic Risk) of 0.0 which indicates the returns on MARKET and SP 500 are completely uncorrelated. Even though it is essential to pay attention to SP 500 Pharmaceuticals existing price patterns, it is always good to be careful when utilizing equity price patterns. Macroaxis approach towards measuring future performance of any index is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. SP 500 exposes twenty-eight different technical indicators which can help you to evaluate its performance.
|Horizon||30 Days Login to change|
SP 500 Pharmaceuticals Relative Risk vs. Return LandscapeIf you would invest 66,862 in SP 500 Pharmaceuticals Indu on September 21, 2019 and sell it today you would lose (155.00) from holding SP 500 Pharmaceuticals Indu or give up 0.23% of portfolio value over 30 days. SP 500 Pharmaceuticals Indu is generating negative expected returns and assumes 0.1639% volatility on return distribution over the 30 days horizon. Simply put, 1% of equities are less volatile than SP 500 and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
Daily Expected Return (%)
SP 500 Market Risk Analysis
Sharpe Ratio = -0.7071
SP 500 Relative Performance Indicators
Estimated Market Risk